UCR 280: Testosterone Pellet Denials, Secondary Payer Prior Auths, and Urology Risk Assessments
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
UCR 280: Testosterone Pellet Denials, Secondary Payer Prior Auths, and Urology Risk Assessments
-
ナレーター：
-
著者：
概要
March 13, 2026
In this episode, Scott, Mark, and Dr. Ray Painter tackle three emerging reimbursement challenges affecting urology practices: widespread denials for testosterone pellet (Testopel®) therapy, the growing trend of secondary payers requiring prior authorization for high-cost drugs, and whether urology questionnaires qualify as billable health risk assessments.
PRS Coding and Reimbursement Hub
Access the Hub
Botox LCD Alert
Download the Alert
Free In-Office Prostate Biopsy Calculator (Suppoted by UC-Care)
Download Now
PRS Coding Courses
For Urologist
For APPs
For Coders, Billers, and Admins
Join the Urology Pharma and Tech Pioneer Group
Empowering urology practices to adopt new technology faster by providing clear reimbursement strategies—ensuring the practice gets paid and patients benefit sooner.
https://www.prsnetwork.com/joinuptp
Click Here to Start Your Free Trial of AUACodingToday.com
The Thriving Urology Practice Facebook group.
The Thriving Urology Practice Facebook Group link to join:
https://www.facebook.com/groups/ThrivingPractice/